Aldeyra Therapeutics, Inc. (ALDX)
$
1.77
-0.07 (-3.95%)
Key metrics
Financial statements
Free cash flow per share
468.6 Thousand
Market cap
106.5 Million
Price to sales ratio
0
Debt to equity
0.3510
Current ratio
2.5813
Income quality
1.2172
Average inventory
0
ROE
-0.0000
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aldeyra Therapeutics, Inc. is a biotechnology company that specializes in developing and commercializing innovative treatments for immune-mediated ocular and systemic diseases. The company reported an income before tax of -$33,846,661.00 showcasing its pre-tax profitability, and it achieved a revenue of $0.00 indicating its niche market focus. Furthermore, the income before tax ratio is 0.00 reflecting the pre-tax margin. As part of its financial operations, the company incurred an interest expense of $1,905,310.00 which underscores its debt servicing obligations. Additionally, the net total of other income and expenses is $1,418,545.00 reflecting non-core financial activities. Aldeyra's lead product candidate, reproxalap, currently in Phase III clinical trials, aims to address dry eye diseases and allergic conjunctivitis. The company is also advancing ADX-629, a first-in-class orally administered RASP modulator presently in Phase II trials for psoriasis, asthma, and COVID-19, alongside ADX-2191, a dihydrofolate reductase inhibitor that is in Phase 3 for the prevention of proliferative vitreoretinopathy and Phase II for retinitis pigmentosa and primary vitreoretinal lymphoma. Additionally, Aldeyra has a license agreement with Madrigal Pharmaceuticals, Inc. for the development of ADX-1612, which targets the protein chaperome for treating inflammatory diseases. The company, originally founded as Aldexa Therapeutics, Inc., rebranded to Aldeyra Therapeutics, Inc. in March 2014 and is headquartered in Lexington, Massachusetts. In the current market landscape, Aldeyra’s stock is affordable at $4.93 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 2,479,708.00 indicating lower market activity. With a market capitalization of $106,523,524.00 the company is classified as a small-cap player in the biotechnology field. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth within the healthcare domain. As Aldeyra Therapeutics continues to develop its product pipeline, it remains committed to addressing urgent medical needs while achieving financial growth and stability.
Is Aldeyra Therapeutics, Inc. (ALDX) a good investment?
Investing in Aldeyra Therapeutics, Inc. (ALDX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Aldeyra Therapeutics, Inc. (ALDX)'s stock forecast?
Analysts predict Aldeyra Therapeutics, Inc. stock to fluctuate between $1.07 (low) and $6.81 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aldeyra Therapeutics, Inc.'s market capitalization?
As of 2026-03-27, Aldeyra Therapeutics, Inc.'s market cap is $106,523,524, based on 60,182,782 outstanding shares.
How does Aldeyra Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Aldeyra Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aldeyra Therapeutics, Inc. (ALDX) stock?
To buy Aldeyra Therapeutics, Inc. (ALDX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALDX. Place an order (Market, Limit, etc.).
What is the best time to invest in Aldeyra Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Aldeyra Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.56 | Growth: -40.43%.
Where can I find Aldeyra Therapeutics, Inc.'s investor relations reports?
Visit https://www.aldeyra.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aldeyra Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Aldeyra Therapeutics, Inc. stock?
All-time high: $11.97 (2023-06-15) | All-time low: $1.07 (2026-03-17).
What are the key trends affecting Aldeyra Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
newsfilecorp.com
New York, New York--(Newsfile Corp. - March 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
globenewswire.com
NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public.
newsfilecorp.com
New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
newsfilecorp.com
New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws. Throughout 2024 and 2025, Aldeyra's made forward-looking statements regarding the development and regulatory prospects of reproxalap for the treatment of dry eye disease.
prnewswire.com
NEW YORK, March 26, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public. So What: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
globenewswire.com
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public.
globenewswire.com
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
globenewswire.com
NEW YORK, March 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public.
prnewswire.com
NEW YORK, March 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public. So What: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public. So What: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran.
See all news
